May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Personality Traits and Objectively Measured Adherence in Glaucoma
Author Affiliations & Notes
  • G. Hollo
    Semmelsweis University, Budapest, Hungary
    Dept of Ophthalmology,
  • P. Kóthy
    Semmelsweis University, Budapest, Hungary
    Dept of Ophthalmology,
  • A. Géczy
    Institute of Psychology, Pázmány Peter Catholic University, Budapest, Hungary
  • P. Vargha
    Semmelsweis University, Budapest, Hungary
    Biometry Unit,
  • Footnotes
    Commercial Relationships  G. Hollo, Alcon, C; Alcon, R; P. Kóthy, None; A. Géczy, None; P. Vargha, None.
  • Footnotes
    Support  Hungarian National Health Grant ETT 001/2006 (GH)
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1589. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Hollo, P. Kóthy, A. Géczy, P. Vargha; Personality Traits and Objectively Measured Adherence in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1589. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate the influence of personality traits on adherence to QD IOP lowering medication.

Methods: : Adherence to QD travoprost was measured with the Travalert® monitoring device on 60 consecutive medically controlled glaucoma patients who had been using travoprost for at least 1 month without drop-related complaints. Following a training on the use of the device topical medication was continued and Travalert® with inactivated alarm function was used for 3 months. Health status, social circumstances, personality traits and anxietas (measured with STAI-S and -T, EPQ, shortened hopeless inventory validated for Hungarian population) were registered. Adherence was defined with instillation of travoprost at 9 p.m. (±2 hours). The ratio of the non-adherent days was used for analysis.

Results: : 58 patients (age: 67.3±14.1 years) used the device. Psychoticism, extroversion and neuroticism did not exceed the normal values (U test, p>0.05). Social desirability (15.05±4.08 points) was significantly higher that the standard (10.13±3.91 points) (U-test, p<0.0001). Non-adherence for the total period was 23.0%. It was 21.2%±29.3% and 26.5 %±31.3% for the first and last 10 days, respectively (Wilcoxon sinked rank test, p=0.027). Life circumstances, education, profession, frequency of visits, glaucoma related QL measures, visual functions, length of glaucoma treatment, number of eye drops and systemic medications, confidence in glaucoma treatment did not influence adherence (Spearman’s correlation, Kruskal-Wallis test p>0.05). Test positivity on the shortened hopeless scale (n=7, 12.1%) confirmed with mild to moderate depression level on the Shortened Beck Depression Inventory was not associated with increased or more frequent non-adherence (Wilcoxon rank sum test, p=0.071, Chi square test, p=0.527).

Conclusions: : Despite objectively measured adherence to QD PG analogue medication was relatively good, it decreased already in the third month after the initial training. Increased social desirability indicates that self-reported adherence is a biased measure. Objective monitoring of adherence showed that in contrast to previous studies using subjective assessment of adherence, mild to moderate depression was not associated with increased non-adherence.

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.